{"entity":{"id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of GR1803 in multiple myeloma, run by Genrix (Shanghai) Biopharmaceutical Co., Ltd., active and no longer recruiting.","summary":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06566547 by Genrix (Shanghai) Biopharmaceutical Co., Ltd., with 116 participants planned, started 2024-08-26 and due to reach its primary completion in 2027-05-12. Interventions recorded: GR1803 injection. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06566547","url":"https://clinicaltrials.gov/study/NCT06566547"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["gr1803"],"companies":["genrix-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06566547","phase":"2","setting":"Single-Arm, Open, Multi-Center Phase II Clinical Trial of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","participation":[{"nct":"NCT06566547","source":"https://clinicaltrials.gov/study/NCT06566547","fetchedAt":"2026-10-07T16:54:48.431Z","studySha256":"862c3e272f2dca99b676db812747d7f22bc19e44fa83716c2811823651e3435b","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-27","leadSponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":116,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-08-26","startedType":"actual","enrolled":116,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06566547/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/"}],"company":[{"id":"genrix-bio","kind":"company","name":"Genrix Bio","route":"/companies/genrix-bio/"}]}}